.png){kind=icon}
.png){kind=icon}
Return
Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthma
.png){kind=icon}
OA
AI
A
J
L
G
B
J
M
A
J
K
J
G
S
T
DOI：10.1002/bcp.70666.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Keywords:
adolescents
asthma
paediatric population
pharmacodynamics
pharmacokinetics
tezepelumab
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3
Papers:
8.5K
Citations:
1.8W
Organization
Cited Papers